S Beslija
Overview
Explore the profile of S Beslija including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer S, et al.
Br J Cancer
. 2014 Oct;
111(11):2051-7.
PMID: 25268370
Background: The randomised phase III TURANDOT trial compared first-line bevacizumab-paclitaxel (BEV-PAC) vs bevacizumab-capecitabine (BEV-CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival...
2.
Lang I, Inbar M, Kahan Z, Greil R, Beslija S, Stemmer S, et al.
Eur J Cancer
. 2012 May;
48(17):3140-9.
PMID: 22640829
Background: We report safety data from a randomised, phase III study (CECOG/BC.1.3.005) evaluating first-line bevacizumab plus paclitaxel or capecitabine for locally recurrent or metastatic breast cancer. Patients And Methods: Patients...
3.
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Heinemann V, et al.
Ann Oncol
. 2009 Jul;
20(11):1771-85.
PMID: 19608616
Background: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care measures. Design: To provide timely and evidence-based recommendations for...
4.
Beslija S, Dizdarevic Z, Lomigoric J, Zutic H, Musanovic M, Mehic B, et al.
J BUON
. 2007 Mar;
10(3):347-55.
PMID: 17357188
Purpose: This randomized phase II trial was conducted to compare the overall response rate (ORR) of gemcitabine plus cisplatin combination followed by sequential radiotherapy (RT) (arm A) versus RT alone...
5.
Beslija S
J BUON
. 2007 Mar;
10(2):175-80.
PMID: 17343325
Breast cancer is the most common cancer and the second most common cause of cancer-related death in women. The last three decades have yielded marked progress in the diagnosis and...
6.
Obralic N, Beslija S
J BUON
. 2007 Feb;
11(1):21-9.
PMID: 17318948
Availability of effective treatment has been shown to have a profound, positive impact on survival of breast cancer patients. However, with passing of time treatment of breast cancer has become...
7.
Jezdic S, Bountouroglou N, Iordanov V, Athanassiou A, Radulovic S, Kinay M, et al.
J BUON
. 2007 Feb;
11(3):277-80.
PMID: 17309149
No abstract available.
8.
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, et al.
Ann Oncol
. 2006 Jul;
18(2):215-25.
PMID: 16831851
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
9.
Kose M, Sufliarsky J, Beslija S, Saip P, Tulunay G, Krejcy K, et al.
Gynecol Oncol
. 2005 Jan;
96(2):374-80.
PMID: 15661224
Objectives: Gemcitabine and carboplatin each have demonstrated effectiveness without increased neurotoxicity in pretreated patients with ovarian cancer. We evaluated the efficacy and safety of gemcitabine plus carboplatin in patients with...
10.
Obralic N, Tahmiscija H, Kobaslija S, Beslija S
Med Arh
. 1999 Jun;
53(1):47-50.
PMID: 10356933
Function and integrity disorders of the oral cavity fall into the most frequent complication of the chemotherapy of leucemias, malignant lymphomas and solid tumors. Complications associated with cancer chemotherapy can...